WASHINGTON — Patients with obesity and metabolic dysfunction-associated fatty liver disease taking glucagon-like peptide-1 receptor agonists had lower risk for all-cause mortality and major cardiovascular events, according to a presenter.
“As a future gastroenterologist and current physician advocating for patients with obesity, my research team and I found a critical need to explore
WASHINGTON — Parental obesity was associated with a nearly threefold increased risk for metabolic dysfunction-associated steatotic liver disease among offspring in early adulthood, according to data presented at Digestive Disease Week.
“Notably, there are no widely adopted screening protocols to identify younger patients with MASLD, as the disease is largely silent and doesn’t
WASHINGTON — Bariatric surgery was associated with improved clinical outcomes and more cost-effective health care resource utilization among patients with metabolic dysfunction-associated steatotic liver disease, according to data.
“Right now, obesity and the metabolic consequences, which include NAFLD, are continuing to increase every year,” Rayna Patel, MD, a second-year
WASHINGTON — Glucagon-like peptide-1 receptor agonists were associated with lower risk for progression to cirrhosis and hepatocellular carcinoma in patients with metabolic dysfunction-associated steatotic liver disease and type 2 diabetes.
“Metabolic dysfunction-associated steatotic liver disease, or MASLD, is a growing cause of cirrhosis and HCC,” Fasiha Kanwal, MD, MSHS,
WASHINGTON — An algorithm that uses electronic health record parameters identified glycemic evidence of new-onset diabetes in real time, which could lead to earlier detection of pancreatic ductal adenocarcinoma, according to researchers.
“In retrospective studies, new-onset diabetes has been associated with a higher risk for pancreatic cancer,” Suresh T. Chari, MD, professor